Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
598.91
-3.91 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Madrigal Pharmaceuticals, Inc. - Common Stock
6 Stocks Positioned to Soar as Investors Focus on MASH
April 22, 2024
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of...
Via
TheNewswire.com
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Via
MarketBeat
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
March 15, 2024
Via
Investor Brand Network
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Via
MarketBeat
Topics
Artificial Intelligence
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
September 13, 2023
Via
Investor Brand Network
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/17 Morning Trading
March 17, 2023
Via
Investor Brand Network
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
May 23, 2023
Via
Investor Brand Network
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
April 18, 2023
Via
Investor Brand Network
Want Diversified Upside in Biotechnology? Check out LABU
March 22, 2023
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.
Via
MarketBeat
Topics
ETFs
Stocks
Why Did Viking Therapeutics Stock Skyrocket
December 21, 2022
VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.
Via
MarketBeat
Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis
December 19, 2022
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
December 19, 2022
Madrigal Pharmaceuticals announced positive results for a major clinical trial and shares are up more than 200% because of it.
Via
MarketBeat
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit